CHA ÀǰúÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • À̼¼Èñ
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : È£Èí±âÁúȯ
  • Á÷ À§: Á¶±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
23 (±¹¿Ü)SCI Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis
22 (±¹¿Ü)SCIE Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD
21 (±¹¿Ü)SCI CT scanning-based phenotypes vary with ADRB2 polymorphisms in chronic obstructive pulmonary disease
20 (±¹¿Ü)SCI Lung Function Response to 12-week Treatment with Combined Inhalation of Long-acting ¥â2 Agonist and Glucocorticoid According to ADRB2 Polymorphism in Patients with Chronic Obstructive Pulmonary Disease
19 (±¹¿Ü)SCI Bronchobiliary fistula treated with histoacryl embolization under bronchoscopic guidance
18 (±¹³»)SCOPUS °áÇÙ¼º ÆÄ±«Æó¿¡ ÀÇÇÑ Æóµ¿¸Æ °íÇ÷¾Ð ȯÀÚ¿¡¼­ ¹ß°ßµÈ ±ÙÀ§ºÎ Æóµ¿¸Æ Ç÷ÀüÁõ 1¿¹
17 (±¹¿Ü)SCI Quantitative Assessment of Emphysema, Air Trapping, and Airway Thickening on Computed Tomography
16 (±¹³»)KCI Myasthenia Gravis Presenting as Isolated Respiratory Failure
15 (±¹³»)SCOPUS Æó¾ÏÀÇ Áø´Ü°Ë»ç Áß ±â°üÁö¼¼Ã´¾×¿¡¼­ ThinPrep°Ë»ç¹ý°ú ±âÁ¸ÀÇ ¼¼Æ÷°Ë»ç¹ýÀÇ À¯¿ë¼º¿¡ ´ëÇÑ ºñ±³
14 (±¹³»)SCOPUS Èä¼öÀÇ °¨º° Áø´Ü ½Ã Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM)ÀÇ À¯¿ë¼º
ÀÌÀüÆäÀÌÁö À̵¿ 11 12 13 14 15 16 17 18 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾Çհǰ­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729